ReiThera
Rome, IT
1 confirmed programs
· 1 sponsors
· Last scored 2026-03-15
59.0
Signal Score
○ FDA Inspections
✓ Clinical Trials (1)
○ SEC Filings
✓ Press (1)
Quick Facts: ReiThera
- Signal Score
- 59.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Rome, IT
- Modalities
- Adenoviral, AAV
- Active CGT Programs
- 1 confirmed from ClinicalTrials.gov across 1 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
1
Sponsors1
ModalitiesAdenoviral, AAV
1 active programs across 1 sponsors
Modalities: AAV, Adenoviral
Source: ClinicalTrials.gov facility matching
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 CGT manufacturing site: Rome, Italy
Modalities: Adenoviral, AAV
Capacity assessment: 58.0/100
Sites: Rome, Italy
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press1 articles
1 CGT manufacturing site: Rome, Italy
Modalities: Adenoviral, AAV
Capacity assessment: 58.0/100
Clinical Activity 1 studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Recent News 1 articles
The New Blueprint for Vaccine Development - The Medicine Maker
The New Blueprint for Vaccine Development The Medicine Maker
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: